Tristel Plc's (LON:TSTL) international expansion continues to drive growth, it said posting a 12% increase in turnover and 22% uplift in overseas sales.
The firm makes infection prevention products and its three markets are in human health, contamination control and animal health.
In the year to June 30, the pre-tax profit was up 27% to £3.3mln against £2.6mln in 2015 on revenues, which were 12% higher at £17.1mln.
The dividend per share for the year is up 11% to 6.33p (2015: 5.72p), including a special divi of 3p a share (2015 special dividend: 3p per share).
Overseas sales were up 22% to £6.7mln compared to £5.5mln in 2015, representing 39% of total sales (2015: 36%).
The group has no debt and had net cash of £5.7mln as at the year end.
Chief executive Paul Swinney said the firm made "very solid progress" during the year.
"...we are succeeding in increasing profit margins, even whilst investing in new products and opening up new geographical markets, including North America.
"The progress we are making with the United States FDA and EPA, and Canada's HPB, is in line with the North American business plan we are developing."
Shares added 0.63% to 161p each.